51 results
Page 2 of 3
6-K
EX-99.1
grs9oqj2 q1x
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
a12w2f ydegsmjbx1
11 Jul 22
Current report (foreign)
4:30pm
F-3/A
a1hyv7
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
fkmikr3486 dpsmj
10 Jun 22
Current report (foreign)
6:05am
F-3/A
6zrvgqyk5zyjnuep5
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
c0j39grz 3lvecc
5 May 22
Current report (foreign)
6:04am
6-K
EX-99.1
ead64ppjozb lt
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
n54srdkdgnnnkmwqkcqo
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
EX-1.2
k7sey09ypdh2 c9qj
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
pbgnewy g8p3
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
356a14w3nh6xzm
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
mvu6 qed37nno8hydur
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
xh8xqc1 pfk0nqevae9c
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
yqc524x
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
ki7 r7d6ag9a3jjf639
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
g519cz
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
0k23ikyb0 3kcqb
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
EX-99.3
exacyq5w1zj z92
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
ptz6537egp4py1q
27 Aug 21
Current report (foreign)
4:10pm
6-K
EX-99.1
gxyjhaiqvg291kn
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am